Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Pfizer (NY: PFE)
38.54 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 5:49 AM EST, Dec 13, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 60
Open 38.54
Bid (Size) 38.56 (2)
Ask (Size) 38.69 (15)
Prev. Close 38.54
Today's Range 38.54 - 38.54
52wk Range 33.97 - 44.90
Shares Outstanding 5,849,571,048
Dividend Yield 3.53%
Performance
YTD
-10.89%
-10.89%
1 Month
+4.25%
+4.25%
3 Month
+3.38%
+3.38%
6 Month
-9.32%
-9.32%
1 Year
-12.73%
-12.73%
Top News
More News
FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved XELJANZ® XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily treatment of... Read More
from Business Wire News Releases
ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing, Co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials
ImmunOs Therapeutics AG, a Swiss bio-technology company and leading developer of a next generation innate immunity focused immunotherapy platform for cancer, announced today the closing of a Series A... Read More
from Business Wire News Releases
More News
Read More
UPDATE 1-GSK's ViiV seeks marketing licence for baby-friendly HIV pill
category companyNews
from Reuters: Company News
IWD, DIS, INTC, PFE: ETF Outflow Alert
category ETFs
from ETF Channel
Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment
from Business Wire News Releases
After Its Celgene Acquisition, Bristol-Myers Squibb's Future Looks Bright
category MRK , Market News , PFE , and 1 more.
from Motley Fool
3 Biotech Stocks That Can Double Your Money in 2020
category JNJ , AMRN , Market News , and 4 more.
from Motley Fool
Why This Pharmaceutical Stock Broke Out Bullishly In Early Action
from Investor's Business Daily
Merck Stock Is On An Upswing In 2019 — Should You Buy This Pharma Stock?
from Investor's Business Daily
Drugmakers have spent a record $342 billion on M&A in 2019
category Company Announcements/Warnings , SNY , Biotechnology , and 19 more.
from MarketWatch
UPDATE 3-Merck pushes deeper into targeted cancer therapy with $2.7 bln ArQule deal
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.